TD-3504

TD-3504 is a small molecule, gastrointestinal-targeted pan-Janus kinase (JAK) inhibitor developed by Theravance Biopharma. It was investigated primarily for the treatment of ulcerative colitis and designed to act locally in the gut to minimize systemic exposure and potential side effects. The drug’s mechanism involves inhibition of JAK enzymes, which play a key role in cytokine signaling pathways involved in immune and inflammatory responses. Clinical development reached Phase 1, where safety, tolerability, and pharmacokinetics were evaluated in both healthy subjects and patients with ulcerative colitis[2][3][5].